Guidelines on the Management of Advanced HIV Disease

What this guideline says

GMJ summary

These guidelines consolidate WHO recommendations (2017–2025) for managing advanced HIV disease, defined as CD4 count ≤200 cells/mm³ in adults, adolescents and children ≥5 years, or all children 1 year. Advanced HIV disease remains a major cause of AIDS-related deaths globally, with TB and cryptococcal disease being the leading opportunistic infections.

The core intervention is a package of care including: CD4 testing to identify advanced disease; screening and prophylaxis for TB, cryptococcal disease and severe bacterial infections; rapid ART initiation (within 7 days, preferably same-day); and intensified adherence support. New 2025 recommendations address CD4 testing as the preferred diagnostic method, post-hospital discharge interventions, and updated Kaposi’s sarcoma treatment with paclitaxel or pegylated liposomal doxorubicin.

The guidelines provide detailed protocols for managing cryptococcal meningitis (including single high-dose liposomal amphotericin B regimens), histoplasmosis, TB in advanced HIV, and other opportunistic infections. Special attention is given to timing of ART initiation, managing raised intracranial pressure, preventing immune reconstitution inflammatory syndrome, and supporting transitions from hospital to community care.

Key points

For clinicians — doses and thresholds as stated in the guideline

1. Advanced HIV disease is defined as CD4 ≤200 cells/mm³ for adults and children ≥5 years; all children <5 years are considered to have advanced disease unless on ART >1 year and clinically stable
2. CD4 testing is strongly recommended as the preferred method to identify advanced HIV disease; WHO clinical staging may be used only where CD4 testing is unavailable (sensitivity 61%, specificity 72%)
3. Cryptococcal antigen screening recommended for CD4 <100 cells/mm³ (strong) or <200 cells/mm³ (conditional); pre-emptive fluconazole 800–1200 mg/day for 2 weeks if CrAg-positive without meningitis
4. Preferred cryptococcal meningitis treatment: single high-dose liposomal amphotericin B 10 mg/kg + flucytosine 100 mg/kg/day + fluconazole 1200 mg/day for 14 days; defer ART 4–6 weeks from antifungal start
5. TB diagnosis in advanced HIV: concurrent testing with low-complexity automated NAATs on respiratory samples and LF-LAM on urine; start ART within 2 weeks of TB treatment (except TB meningitis: defer 4–6 weeks)
6. TB preventive treatment: 3HP (3 months rifapentine + isoniazid weekly) is preferred regimen for adults and adolescents; alternatives are 6H or 9H
7. Kaposi's sarcoma treatment: paclitaxel or pegylated liposomal doxorubicin for pharmacological treatment; immediate ART for mild/moderate disease, ART + chemotherapy for severe disease
8. Post-discharge interventions may include: pre-discharge goal setting, medication review, transitional care planning, telephone follow-up, home visits by health workers/peer supporters

Components of the WHO-recommended advanced HIV disease package of care for adults, adolescents and children

Table extracted from the guideline

Source: World Health Organization, Guidelines on the Management of Advanced HIV Disease. Reproduced in summary form.

What changed in this edition

Versus the previous edition

• New 2025 recommendation: CD4 testing is the strongly recommended preferred method to identify advanced HIV disease (moderate-certainty evidence); WHO clinical staging may be used only where CD4 unavailable (conditional, very-low-certainty)
• New 2025 recommendation: hospitalized people with HIV may be provided interventions to support transitions to outpatient care (pre-discharge goal setting, medication review, telephone follow-up, home visits)
• New 2025 recommendation: paclitaxel or pegylated liposomal doxorubicin suggested for pharmacological treatment of Kaposi's sarcoma (conditional, low-certainty evidence)
• Updated 2022 cryptococcal meningitis treatment: single high-dose liposomal amphotericin B 10 mg/kg regimen now preferred over 14-day standard dosing
• Consolidated recommendations from multiple 2017–2025 guidelines into single comprehensive document

Editor’s perspective

Why this matters for Georgia and the region

Applicability

Georgia and the South Caucasus

Questions this guideline answers

Quick answers

Related on GMJ

Interconnected resources

GMJ Guidelines Library records are original summaries written by the GMJ editorial team from the issuer’s published document and reviewed by a physician. They do not replace the full guideline. The document is the copyright of its issuer and is linked, not hosted. Spotted an error or a newer edition? Tell the Guidelines Desk.